Diabetes Symposium Evaluation - October 14, 2017

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Apply updated guidelines in the management of patients in a hyperglycemic crisis.	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 5	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 4	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 3	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 2	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 1	Apply updated guidelines in the management of patients in a hyperglycemic crisis. - 0
Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis.	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 5	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 4	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 3	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 2	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 1	Utilize a triage system to determine best location of care and therapeutic approach for patients during a hyperglycemic crisis. - 0
Examine results of cardiovascular disease trials that include type 2 diabetes management agents.	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 5	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 4	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 3	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 2	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 1	Examine results of cardiovascular disease trials that include type 2 diabetes management agents. - 0
Implement a cardiodiabetological approach to patient care.	Implement a cardiodiabetological approach to patient care. - 5	Implement a cardiodiabetological approach to patient care. - 4	Implement a cardiodiabetological approach to patient care. - 3	Implement a cardiodiabetological approach to patient care. - 2	Implement a cardiodiabetological approach to patient care. - 1	Implement a cardiodiabetological approach to patient care. - 0
Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control.	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 5	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 4	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 3	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 2	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 1	Approach diabetes as a multifaceted disorder by addressing factors beyond glucose control. - 0
Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy.	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 5	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 4	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 3	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 2	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 1	Discuss method to address risk factors for recurrent diabetic ketoacidosis (DKA) prior to discharge. Identify the risk factors for diabetic retinopathy. - 0
Describe and distinguish between the stages of diabetic retinopahty.	Describe and distinguish between the stages of diabetic retinopahty. - 5	Describe and distinguish between the stages of diabetic retinopahty. - 4	Describe and distinguish between the stages of diabetic retinopahty. - 3	Describe and distinguish between the stages of diabetic retinopahty. - 2	Describe and distinguish between the stages of diabetic retinopahty. - 1	Describe and distinguish between the stages of diabetic retinopahty. - 0
Explain current technologies for glucose monitoring and current practice guidelines.	Explain current technologies for glucose monitoring and current practice guidelines. - 5	Explain current technologies for glucose monitoring and current practice guidelines. - 4	Explain current technologies for glucose monitoring and current practice guidelines. - 3	Explain current technologies for glucose monitoring and current practice guidelines. - 2	Explain current technologies for glucose monitoring and current practice guidelines. - 1	Explain current technologies for glucose monitoring and current practice guidelines. - 0
Identify current and emerging technologies for insulin subcut infusion therapy.	Identify current and emerging technologies for insulin subcut infusion therapy. - 5	Identify current and emerging technologies for insulin subcut infusion therapy. - 4	Identify current and emerging technologies for insulin subcut infusion therapy. - 3	Identify current and emerging technologies for insulin subcut infusion therapy. - 2	Identify current and emerging technologies for insulin subcut infusion therapy. - 1	Identify current and emerging technologies for insulin subcut infusion therapy. - 0
List current technology options for population management of diabetic patients with diabetes using technology.	List current technology options for population management of diabetic patients with diabetes using technology. - 5	List current technology options for population management of diabetic patients with diabetes using technology. - 4	List current technology options for population management of diabetic patients with diabetes using technology. - 3	List current technology options for population management of diabetic patients with diabetes using technology. - 2	List current technology options for population management of diabetic patients with diabetes using technology. - 1	List current technology options for population management of diabetic patients with diabetes using technology. - 0
Assist patients with implementing self-care behaviors to improve quality of life.	Assist patients with implementing self-care behaviors to improve quality of life. - 5	Assist patients with implementing self-care behaviors to improve quality of life. - 4	Assist patients with implementing self-care behaviors to improve quality of life. - 3	Assist patients with implementing self-care behaviors to improve quality of life. - 2	Assist patients with implementing self-care behaviors to improve quality of life. - 1	Assist patients with implementing self-care behaviors to improve quality of life. - 0
Demonstrate how active collaboration with a healthcare team will improve clinical outcomes.	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 5	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 4	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 3	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 2	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 1	Demonstrate how active collaboration with a healthcare team will improve clinical outcomes. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D.	Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D. - 5	Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D. - 4	Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D. - 3	Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D. - 2	Hyperglycemic Crisis: What’s New, What’s Not and What’s Next? - Marie E. McDonnell, M.D. - 1
Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D.	Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D. - 5	Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D. - 4	Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D. - 3	Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D. - 2	Diabetes and Cardiovascular Disease - Paul Aoun, D.O., Ph.D. - 1
Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D.	Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D. - 5	Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D. - 4	Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D. - 3	Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D. - 2	Epidemiology and Diagnosis of Diabetic Retinopathy - Andrew M. Schimel, M.D. - 1
New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D.	New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D. - 5	New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D. - 4	New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D. - 3	New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D. - 2	New Frontiers in Diabetes Technology - Marie E. McDonnel, M.D. - 1
Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D.	Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D. - 5	Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D. - 4	Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D. - 3	Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D. - 2	Patient Centered Diabetes Care – Challenges and Solutions - Paul Aoun, D.O., Ph.D. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

No

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

No

If you checked "No,” please tell us why: *

Would you recommend this symposium to a colleague? *

If you checked "No,” please explain why you would not recommend this course: *

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

You are here

Diabetes Symposium Evaluation - October 14, 2017